Contribution of Immunoscore to Survival Prediction in Pancreatic Ductal Adenocarcinoma.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-10-01 DOI:10.21873/anticanres.17277

Haruki Mori, Toru Miyake, Hiromitsu Maehira, Masanori Shiohara, Hiroya Iida, Nobuhito Nitta, Masaji Tani

{"title":"Contribution of Immunoscore to Survival Prediction in Pancreatic Ductal Adenocarcinoma.","authors":"Haruki Mori, Toru Miyake, Hiromitsu Maehira, Masanori Shiohara, Hiroya Iida, Nobuhito Nitta, Masaji Tani","doi":"10.21873/anticanres.17277","DOIUrl":null,"url":null,"abstract":"Background/aim: The presence of tumor-infiltrating lymphocytes (TILs) has been demonstrated as a prognostic factor in colorectal cancer after surgical resection of malignancy, but knowledge on their role in pancreatic cancer is lacking. The Immunoscore (IS) assesses TILs at the core of the tumor (CT) and invasive margin (IM) and is being evaluated as a new concept in tumor immunity. The aim of this study was to evaluate the relationship between IS and prognosis in PDAC.Patients and methods: The IS was analyzed by immunohistochemistry using surgical tissue blocks from 131 patients with pancreatic ductal adenocarcinoma (PDAC) who underwent surgery to investigate the relationship between immune cell infiltration into the tumor and prognosis in PDAC.Results: A high IS in both CT and IM of the tumor was significantly associated with prolonged overall survival (OS) (p<0.01) and relapse-free survival (RFS) (p<0.01). In multivariate logistic regression models adjusted for clinical pathology data, IS predicted survival and recurrence (p<0.01 and p<0.01, respectively). Moreover, in patients who received preoperative chemotherapy, a high IS was statistically significantly associated with longer OS and RFS (p<0.01 and p<0.01, respectively).Conclusion: The immunohistochemically assessed IS might be a useful prognostic marker for patients with PDAC who underwent primary tumor resection.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4483-4492"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The presence of tumor-infiltrating lymphocytes (TILs) has been demonstrated as a prognostic factor in colorectal cancer after surgical resection of malignancy, but knowledge on their role in pancreatic cancer is lacking. The Immunoscore (IS) assesses TILs at the core of the tumor (CT) and invasive margin (IM) and is being evaluated as a new concept in tumor immunity. The aim of this study was to evaluate the relationship between IS and prognosis in PDAC.

Patients and methods: The IS was analyzed by immunohistochemistry using surgical tissue blocks from 131 patients with pancreatic ductal adenocarcinoma (PDAC) who underwent surgery to investigate the relationship between immune cell infiltration into the tumor and prognosis in PDAC.

Results: A high IS in both CT and IM of the tumor was significantly associated with prolonged overall survival (OS) (p<0.01) and relapse-free survival (RFS) (p<0.01). In multivariate logistic regression models adjusted for clinical pathology data, IS predicted survival and recurrence (p<0.01 and p<0.01, respectively). Moreover, in patients who received preoperative chemotherapy, a high IS was statistically significantly associated with longer OS and RFS (p<0.01 and p<0.01, respectively).

Conclusion: The immunohistochemically assessed IS might be a useful prognostic marker for patients with PDAC who underwent primary tumor resection.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫评分对胰腺导管腺癌生存预测的贡献

背景/目的：肿瘤浸润淋巴细胞（TILs）的存在已被证明是结直肠癌恶性肿瘤手术切除后的预后因素，但对其在胰腺癌中的作用还缺乏了解。Immunoscore（IS）可评估肿瘤核心（CT）和浸润边缘（IM）的TIL，目前正作为肿瘤免疫的新概念进行评估。本研究旨在评估IS与PDAC预后之间的关系：使用 131 例接受手术的胰腺导管腺癌（PDAC）患者的手术组织块，通过免疫组化对 IS 进行分析，以研究免疫细胞浸润肿瘤与 PDAC 预后之间的关系：结果：肿瘤 CT 和 IM 中的高 IS 与总生存期（OS）的延长明显相关（p 结论：免疫组化评估的肿瘤 CT 和 IM 中的高 IS 与总生存期（OS）的延长明显相关：免疫组化评估的IS可能是接受原发性肿瘤切除术的PDAC患者的有用预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.